respiratory

MRC – Deadline: 28 Jun 2018

Biomedical Catalyst: Regenerative Medicine Research Committee

Supports translation of fundamental discoveries toward benefits to human health.

The translation of the burgeoning knowledge in regenerative medicine into new treatment strategies is a key objective of the MRC’s strategic plan. The Biomedical Catalyst: Regenerative Medicine Research Committee (RMRC) provides support for high quality proposals that may underpin or progress the development of  regenerative medicine therapies to improve human health. The RMRC:

  • Supports confidence in concept studies that if successful will promote the translation of fundamental discoveries toward benefits to human health, thereby accelerating the transition from discovery research to mature translational development projects
  • Funds preliminary work or feasibility studies to establish the viability of an approach, through addressing focussed research questions needed to unlock progress in pre-clinical development and/or early clinical testing of novel regenerative medicine therapies
  • Forms part of the MRC’s Translational Research Strategy and forms part of the Biomedical Catalyst funding stream, operating in conjunction with the Developmental Pathway Funding Scheme

For more information please visit the MRC website.

Advertisements

British Lung Foundation – 16 Jul 2018

Travel Awards

The British Lung Foundation offers travel awards to the European Respiratory Society and American Thoracic Society Conferences. These travel awards are available to early-career clinical and/or non-clinical researchers in the respiratory field and contribute towards the costs of registration, accommodation and travel to assist in the attendance of these important meetings.

European Respiratory Society conference

This year we are offering travel award types to the ERS International Congress in Paris, 15-19 September 2018:

  1. British Lung Foundation awards and British Lung Foundation – British Paediatric Respiratory Society awards
  2. British Lung Foundation – NAPP Pharmaceuticals Ltd awards
  3. British Lung Foundation – King’s College London respiratory and sleep physiology fellowship (travel) award

1. British Lung Foundation awards and British Lung Foundation – British Paediatric Respiratory Society awards

4 British Lung Foundation Travel Fellowships worth £750 each are available for early-career clinical and non-clinical researchers in the respiratory field to attend the European Respiratory Society International Congress 2018.

In addition, the British Lung Foundation and the British Paediatric Respiratory Society (BPRS) are co-funding 2 ERS Travel Fellowships of £750 each, available to paediatric respiratory researchers, with preference to those who have been a member of the BPRS for a minimum of 12 months.

2. British Lung Foundation – NAPP Pharmaceuticals Ltd awards

10 British Lung Foundation-Napp Pharmaceuticals Limited Travel Fellowships worth £750 each are available for early-career health care professionals conducting research in the respiratory field in the UK to attend the European Respiratory Society International Congress 2018. Please read the accompanying guidelines before completing an application form.

3. British Lung Foundation – King’s College London respiratory and sleep physiology fellowship (travel) award

One British Lung Foundation-King’s College London Travel Fellowship worth £750 is available for early-career clinical and non-clinical researchers working in the respiratory and sleep physiology field to attend the European Respiratory Society International Congress 2018. Please read the accompanying guidelines before completing an application form.

Funding decisions will be made known to all applicants by late August/early September 2018. For more information please visit the BLF website.

British Society for Allergy and Clinical Immunology – Deadline 23 Jul 2018

Travel fellowship scheme

These assist with attendance at the annual meeting. Applications from both BSACI and non BSACI members are accepted . If your application is accepted you could receive the following funding depending on the number of nights you will be staying.

One night stay = £200

Two nights stay = £300

Three nights stay = £400

We are proud that this scheme is supporting an increase in attendance and involvement amongst students and healthcare professionals who have less access to financial resources. With the increasing number of Travel Fellowship applications, we are limiting applications to delegates submitting accepted abstracts who are trainees, students, nurses or allied health professionals. When allocating funds priority will be given to BSACI members. Fellowships will be awarded on the grounds of those perceived to be in most financial need or having incurred the greatest expense to attend, rather than on the particular strength of their abstract itself. This is consistent with our wish to make the annual meeting as inclusive as possible. In 2017 the average level of funds allocated was between £200 and £250. If you have any questions please contact bsaci@medivents.co.uk

How to apply

Please send an email to bsaci@medivents.co.uk no later than 9am on Monday 23rd July to include the following:

  1. A supporting letter from your head of department
  2. Covering letter from yourself indicating the number of nights you are staying.
  3. Confirmation of your accepted abstract

You will be notified of the outcome of your application by email around 1st August. If you are successful your travel and accommodation costs will be reimbursed up to your allocated amount on production of relevant receipts after the Meeting.

If you want to know more about this scheme please visit the BSACI website.

MRC – Deadline: 25 Jul 2018

Biomedical Catalyst: Developmental Pathway Funding Scheme (DPFS)

The DPFS scheme is a key part of our Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies.

Remit

The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.

Projects supported by the scheme have up to four clearly defined milestones, outcomes and future plans. These help to maximise both the chance of success and the likelihood of the project attracting the downstream funding, from public or private sources, required to meet its clinical and commercial aims. The funding panels assessing the project will, if necessary, help to develop proposals and suggest enhancements.

The following activities are eligible for support:

  • Developing candidate therapeutic entities (e.g. drug discovery)
  • Pre-clinical testing of novel therapeutic entities
  • Early-phase clinical studies of novel therapeutic entities (phases 1 and 2)
  • “Repurposing” clinical studies – using existing therapies for new indications
  • Developing and testing novel devices
  • Developing and testing diagnostics (including biomarker validation)

Individual projects can start and finish at any point along the translational pathway but would not typically progress from initial development through to phase 2 clinical testing in a single application. Where there is a justified need for continued MRC support, sequential applications are encouraged.

All disease areas (including those relevant to global health) and modalities of intervention are eligible for support from the scheme, including small molecules, peptides, antibodies, vaccines, cell and gene therapy, devices, surgical techniques and psychological approaches.

 

For more information please visit the MRC website.

AstraZeneca – Deadline 1 Aug 2018

Novel Disease Mechanisms for AstraZeneca Preclinical Compounds – innocentive Challenge

AstraZeneca is in the unique position to provide a selection of high-quality tool compounds to create valuable opportunities to explore disease biology in the preclinical setting. AstraZeneca desires proposals that link one or more of these compounds to the following therapeutic areas: respiratory disease, cardiovascular disease, renal disease, or diabetes.

AstraZeneca intends to make up to 5 awards from a total award pool of $50,000. Winning proposals could be selected to receive up to $50,000 in additional research funding.

Pharmaceutical R&D faces several significant challenges in terms of identifying drug targets that translate from basic science into clinical projects and then ultimately into medicines that make a difference to the lives of patients. For every medicine that is prescribed, there are many other drug candidates which do not reach the approval stage. Some of these molecules have been studied extensively and their behavior is well characterized in vitro and in vivo. The availability of high-quality tool compounds enables potential mechanisms of disease to be investigated that may provide novel insights into the biology of the disease and hopefully better translation into the clinic.

This Theoretical Challenge requires only a written proposal. For more information please visit the Innocentive webpage.

MRC – Deadline: 5 Sep 2018

Programme grants – Molecular & Cellular Medicine – Research boards

Suitable for focused research projects. Grants are usually worth up to £1 million on the basis of 80 per cent of full economic costs of the research, for a maximum period of five years.

More information about this call can be found at the MRC website.

 

NIHR – Deadline: 19 Sep 2018

Health technology assessment programme – commissioned workstream – stage 1

The Health Technology Assessment (HTA) Programme funds research about the clinical and cost effectiveness and broader impact of healthcare treatments and tests for those who plan, provide or receive care from NHS and social care services.  HTA research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best.

18/52 – Management of isolated or incidental subsegmental pulmonary embolism

For more information visit the NIHR website.

 

 

NIHR – Deadline: 26 Sep 2018

Health technology assessment programme – commissioned workstream – stage 1

The Health Technology Assessment (HTA) Programme funds research about the clinical and cost effectiveness and broader impact of healthcare treatments and tests for those who plan, provide or receive care from NHS and social care services.  HTA research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best.

18/42 Cystic fibrosis

For more information visit the NIHR website.